NEPH NEPHROS INC

Nasdaq nephros.com


$ 5.33 $ 0.11 (2.04 %)    

Wednesday, 15-Oct-2025 19:19:49 EDT
QQQ $ 602.61 $ 4.22 (0.71 %)
DIA $ 463.04 $ 0.00 (0 %)
SPY $ 665.11 $ 2.94 (0.44 %)
TLT $ 90.76 $ -0.20 (-0.22 %)
GLD $ 387.41 $ 6.60 (1.73 %)
$ 5.49
$ 5.48
$ 5.32 x 100
$ 5.87 x 50
$ 5.39 - $ 5.73
$ 1.36 - $ 5.98
38,213
na
58.2M
$ 0.44
$ 45.18
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-15-2025 03-31-2025 10-Q
3 03-24-2025 12-31-2024 10-K
4 11-14-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 03-15-2024 12-31-2023 10-K
8 11-08-2023 09-30-2023 10-Q
9 08-09-2023 06-30-2023 10-Q
10 05-10-2023 03-31-2023 10-Q
11 03-23-2023 12-31-2022 10-K
12 11-15-2022 09-30-2022 10-Q
13 08-15-2022 06-30-2022 10-Q
14 05-05-2022 03-31-2022 10-Q
15 03-03-2022 12-31-2021 10-K
16 11-04-2021 09-30-2021 10-Q
17 08-05-2021 06-30-2021 10-Q
18 05-06-2021 03-31-2021 10-Q
19 03-01-2021 12-31-2020 10-K
20 11-05-2020 09-30-2020 10-Q
21 08-05-2020 06-30-2020 10-Q
22 05-06-2020 03-31-2020 10-Q
23 02-27-2020 12-31-2019 10-K
24 11-06-2019 09-30-2019 10-Q
25 08-07-2019 06-30-2019 10-Q
26 05-08-2019 03-31-2019 10-Q
27 03-12-2019 12-31-2018 10-K
28 11-08-2018 09-30-2018 10-Q
29 08-08-2018 06-30-2018 10-Q
30 05-09-2018 03-31-2018 10-Q
31 02-26-2018 12-31-2017 10-K
32 11-09-2017 09-30-2017 10-Q
33 08-08-2017 06-30-2017 10-Q
34 05-09-2017 03-31-2017 10-Q
35 03-20-2017 12-31-2016 10-K
36 11-10-2016 09-30-2016 10-Q
37 08-08-2016 06-30-2016 10-Q
38 05-11-2016 03-31-2016 10-Q
39 03-30-2016 12-31-2015 10-K
40 11-10-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 maxim-group-maintains-buy-on-nephros-raises-price-target-to-6

Maxim Group analyst Anthony Vendetti maintains Nephros (NASDAQ:NEPH) with a Buy and raises the price target from $4.5 to $6.

 nephros-q2-eps-002-beats-003-estimate-sales-442m-beat-365m-estimate

Nephros (NASDAQ:NEPH) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $(0.03) by 18...

 nephros-q1-eps-005-beats-001-estimate-sales-488m-beat-365m-estimate

Nephros (NASDAQ:NEPH) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $(0.01) by 60...

 benchmark-reiterates-speculative-buy-on-nephros-maintains-5-price-target

Benchmark analyst Robert Wasserman reiterates Nephros (NASDAQ:NEPH) with a Speculative Buy and maintains $5 price target.

 nephros-q3-2024-gaap-eps-002-beats-002-estimate-sales-3500m-beat-3499m-estimate

Nephros (NASDAQ:NEPH) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $(0.02) by 20...

 nephros-q3-sales-350m-inline
Nephros Q3 Sales $3.50M Inline
11/07/2024 22:01:49

Nephros (NASDAQ:NEPH) reported quarterly sales of $3.50 million which met the analyst consensus estimate. This is a 6.47 perce...

 nephros-q2-eps-003-misses-001-estimate-sales-325m-miss-386m-estimate

Nephros (NASDAQ:NEPH) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $(0.01) by ...

 benchmark-reiterates-speculative-buy-on-nephros-maintains-5-price-target

Benchmark analyst Robert Wasserman reiterates Nephros (NASDAQ:NEPH) with a Speculative Buy and maintains $5 price target.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION